Anticonvulsants in sports: Ethical considerations

Epilepsy and Behavior

Volumn 10, Issue 2, 2007, Pages 268-271

  Kaufman, Kenneth R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anticonvulsants; Doping; Epilepsy; Ethics; Lamotrigine; Levetiracetam; Psychiatry; Sports; Therapeutic use exemption; Tiagabine; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA CARBOLINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOZAPINE; DIAZEPAM; ETIRACETAM; GABAPENTIN; GLUTAMATE RECEPTOR; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; PRIMIDONE; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZINC; ZONISAMIDE;

ADJUVANT THERAPY; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; ATHLETE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BORDERLINE STATE; DOPING; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG INFORMATION; DRUG LEGISLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MEDICAL ETHICS; MEDICAL LITERATURE; MIXED MANIA AND DEPRESSION; MONOTHERAPY; MOOD; NONHUMAN; ORGANIZATION; POLICY; POSTTRAUMATIC STRESS DISORDER; RAPID CYCLING BIPOLAR DISORDER; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL PHOBIA; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ANTICONVULSANTS; DOPING IN SPORTS; HUMANS; NIPECOTIC ACIDS; PIRACETAM; TRIAZINES;

EID: 33947269763     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2006.12.004     Document Type: Article

References (70)

1. World Anti-Doping Code (in force as of 1 January 2003). , 2006 (accessed 25.06.06).
2. World Anti-Doping Code International Standard for Therapeutic Use Exemptions (in force as of 1 January 2005). , 2006 (accessed 25.6.06).
3. World Anti-Doping Code 2006 Prohibited List International Standard (in force as of 1 January 2006). , 2006 (accessed 25.6.06).
4. Kaufman K.R. Modafinil in sports: ethical considerations. Br J Sports Med 39 (2005) 241-244
5. In: Siekmann R.C.R., Soek J., and Bellani A. (Eds). Doping rules of sports federations (1999), TMC Asser Press, The Hague
6. Pass with Flying Colors. , 2006 (accessed 26.6.06).
7. Rigo J.M., Hans G., Nguyen L., et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136 (2002) 659-672
8. Madeja M., Margineanu D.G., Gorji A., et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?. Neuropharmacology 45 (2003) 661-671
9. Lukyanetz E.A., Shkryl V.M., and Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43 (2002) 9-18
10. Lynch B.A., Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101 26 (2004) 9861-9866
11. Lamberty Y., Gower A.J., and Klitgaard H. The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol 439 (2002) 101-106
12. Lamberty Y., Falter U., Gower A.J., and Klitgaard H. Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat. Eur J Pharmacol 469 (2003) 97-102
13. Gower A.J., Falter U., and Lamberty Y. Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat. Eur J Pharmacol 481 (2003) 67-74
14. Lamberty Y., Margineanu D.G., and Klitgaard H. Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav 2 (2001) 454-459
15. Kinrys G., Wygant L.E., Pardo T.B., and Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 67 (2006) 211-214
16. Simon N.M., Worthington J.J., Doyle A.C., et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 65 (2004) 1219-1222
17. Grunze H., Langosch J., Born C., Schaub G., and Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 64 (2003) 781-784
18. Kaufman K.R. Monotherapy treatment of bipolar disorder with levetiracetam. Epilepsy Behav 5 (2004) 1017-1020
19. Braunig P., and Kruger S. Levetiracetam in the treatment of rapid cycling bipolar disorder. J Psychopharmacol 17 (2003) 239-241
20. Schachter S.C. A review of the antiepileptic drug tiagabine. Clin Neuropharmacol 22 (1999) 312-317
21. Sill G.J. Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine. Epileptic Disord 5 (2003) 51-56
22. Schmitt U., Luddens H., and Hiemke C. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J Neural Transmission 109 (2002) 871-880
23. Zwanzger P., Eser D., Padberg F., et al. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depression Anxiety 18 (2003) 140-143
24. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64 (2003) 1245-1249
25. Zwanzger P., and Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry and Neurosci 30 (2005) 167-175
26. Schwartz T.L., Azhar N., Husain J., et al. An open-label study of tiagabine as augmentation therapy for anxiety. Ann Clin Psychiatry 17 (2005) 167-172
27. Schaller J.L., Thomas J., and Rawlings D. Low-dose tiagabine effectiveness in anxiety disorders. Medscape Gen Med 6 3 (2004) 8
28. Schwartz T.L. The use of tiagabine augmentation for treatment resistant anxiety disorders: a case series. Psychopharmacol Bull 36 (2002) 53-57
29. Connor K.M., Davidson J.R., Weisler R.H., Zhang W., and Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berlin) 184 (2006) 21-25
30. Hoffman D.A. Tiagabine for rage, aggression, and anxiety. J Neuropsychiatry Clin Neurosci 17 (2005) 252
31. Carpenter L.L., Schecter J.M., Tyrka A.R., et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 67 (2006) 66-71
32. Kaufman K.R. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 10 (1998) 181-184
33. Carta M.G., Hardoy M.C., Grunze H., and Capiniello B. The use of tiagabine in affective disorders. Pharmacotherapy 35 (2002) 33-34
34. Schaffer L.C., Schaffer C.B., and Howe J. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 71 (2002) 259-263
35. Suppes T., Chisholm K.A., Dhavale D., et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 4 (2002) 282-289
36. Messenheimer J.A. Lamotrigine. Epilepsia 36 Suppl. 2 (1995) S87-S94
37. Wang S.J., Sihra T.S., and Gean P.W. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. NeuroReport 12 (2001) 2255-2258
38. Ketter T.A., Manji H., and Post R. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 23 (2003) 484-495
39. Bourin M., Masse F., and Hascoet M. Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. J Psychiatry Neurosci 30 (2005) 275-282
40. Mirza N.R., Bright J.L., Stanhope K.J., Wyatt A., and Harrington N.R. Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?. Psychopharmacology (Berlin) 180 (2005) 159-168
41. Arban R., Maraia G., Brackenborough K., et al. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 158 (2005) 123-132
42. Goldsmith D.R., Wagstaff A.J., Ibbotson T., and Perry C.M. Lamotrigine: a review of its use in bipolar disorder. Drugs 63 (2003) 2029-2050
43. Barbee J.G., and Jamhour N.J. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 63 (2002) 737-741
44. Rocha F.L., and Hara C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 18 (2004) 97-99
45. Gutierrez R.L., McKercher R.M., Galea J., and Jamison K.L. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectrums 10 (2005) 800-805
46. Hertzberg M.A., Butterfield M.I., Feldman M.E., et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 45 (1999) 1226-1229
47. Dursun S.M., and Deakin J.F.W. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 15 (2001) 297-301
48. Tiihonen J., Hallikainen T., Ryynanen O.P., et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54 (2003) 1241-1248
49. Large C.H., Webster E.L., and Goff D.C. The potential role of lamotrigine in schizophrenia. J Psychopharmacol (Berl) 181 (2005) 415-436
50. Pinto O.C., and Akiskal H.S. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 51 (1998) 333-343
51. Gaitazis A., Carroll K., Majeed A., and Sander J.W. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 45 (2004) 1613-1622
52. Reyenburg S., Mitchell A.J., Schmidt D., Elger C.E., and Reuber M. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav 7 (2005) 161-171
53. Gilliam F.G. Diagnosis and treatment of mood disorders in persons with epilepsy. Curr Opin Neurol 18 (2005) 129-133
54. Mensah S.A., Beavis J.M., Thapar A.K., and Kerr M. The presence and clinical implications of depression in a community population of adults with epilepsy. Epilepsy Behav 8 (2006) 213-219
55. Ettinger A.B., Kustra R.P., and Hammer A.E. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav (2006) [Epub ahead of print]
56. Ovsiew F. Antiepileptic drugs in psychiatry. J Neurol Neurosurg Psychiatry 75 (2004) 1655-1661
57. Mishory A., Yaroslavsky Y., Bersudsky Y., and Belmaker R.H. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 157 (2000) 463-465
58. Nemets B., Bersudsky Y., and Belmaker R.H. Controlled double-blind trial of phenytoin vs fluoxetine in major depressive disorder. J Clin Psychiatry 66 (2005) 586-590
59. Schaffer L.C., Schaffer C.B., and Caretto J. The use of primidone in the treatment of refractory bipolar disorder. Ann Clin Psychiatry 11 (1999) 61-66
60. Bowden C.L. Valproate. Bipolar Disord 5 (2003) 189-202
61. Pande A.C., Davidson J.R., Jefferson J.W., et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19 (1999) 341-348
62. Pande A.C., Pollack M.H., Crockett J., et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20 4 (2000) 467-471
63. Hoopes S.P., Reimherr F.W., Hedges D.W., et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial: Part 1. Improvement in binge and purge measures. J Clin Psychiatry 64 (2003) 1335-1341
64. Hedges D.W., Reimherr F.W., Hoopes S.P., et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial: Part 2. Improvement in psychiatric measures. J Clin Psychiatry 64 (2003) 1449-1454
65. McElroy S.L., Arnold L.M., Shapira N.A., et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 160 (2003) 255-261
66. Johnson B.A., Ait-Daoud N., Bowden C.L., et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 361 (2003) 1677-1685
67. McElroy S.L., Kotwal R., Hudson J.I., Nelson E.B., and Keck P.E. Zonisamide in the treatment of binge-eating: an open-label, prospective trial. J Clin Psychiatry 65 (2004) 50-56
68. Ghaemi S.N., Zablotsky B., Filkowski M.M., et al. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 26 (2006) 385-388
69. Rickels K., Pollack M.H., Feltner D.E., et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62 (2005) 1022-1030
70. Fraser A.D. Doping control from a global and national perspective. Ther Drug Monit 26 (2004) 171-174